Micafungin for the prophylaxis and treatment of Candida infections

References

• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39(3), 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis.41(9), 1232–1239 (2005).
   PubMed Web of Science ®Google Scholar
• Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis.27(4), 781–788 (1998).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit. Care Med.34(3), 857–863 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev.20(1), 133–163 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas PG. Invasive candidiasis. Infect. Dis. Clin. North Am.20(3), 485–506 (2006).
   PubMed Web of Science ®Google Scholar
• Barrett D. From natural products to clinically useful antifungals. Biochim. Biophys. Acta.1587(2–3), 224–233 (2002).
   PubMedGoogle Scholar
• Tawara S, Ikeda F, Maki K et al. in vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents. Chemother.44(1), 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Mikamo H, Sato Y, Tamaya T. in vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother.46(3), 485–487 (2000).
   PubMed Web of Science ®Google Scholar
• Mycamine® (micafungin sodium) product information: Astellas Pharma, OK, USA, June (2006).
   Google Scholar
• Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol.48, 471–497 (1994).
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol.3(3), 98–104 (1995).
   PubMedGoogle Scholar
• Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays28(8), 799–808 (2006).
   PubMed Web of Science ®Google Scholar
• Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother.50(7), 2522–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis.42(7), 938–944 (2006).
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother.49(2), 767–769 (2005).
   PubMed Web of Science ®Google Scholar
• Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother.57(4). 705–708 (2006).
   PubMed Web of Science ®Google Scholar
• Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy26(6). 877–880 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucansynthase. Antimicrob. Agents Chemother.51(5), 1876–1878 (2007).
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother.49(8), 3264–3273 (2005).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin. Microbiol.44(3), 760–763 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol.44(10), 3533–3538 (2006).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother.47(10), 3149–3154 (2003).
   PubMed Web of Science ®Google Scholar
• Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother.54(6), 1051–1056 (2004).
   PubMed Web of Science ®Google Scholar
• Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother.53(2), 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol.44(2), 324–326 (2006).
   PubMed Web of Science ®Google Scholar
• Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother.51(6), 2253–2256 (2007).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. in vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother.51(5), 1616–1620 (2007).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol.43(11), 5425–5427 (2005).
   PubMed Web of Science ®Google Scholar
• Holm SE, Tornqvist IO, Cars O. Paradoxical effects of antibiotics. Scand. J. Infect. Dis. Suppl.74, 113–117 (1990).
   PubMedGoogle Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother.50(4), 1293–7129 (2006).
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother.48(9), 3407–3411 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis.51(3), 173–178 (2005).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother.51(6), 2257–2259 (2007).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother.49(12), 5146–5148 (2005).
   PubMed Web of Science ®Google Scholar
• Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol.11(1), 30–36 (2003).
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. Candida biofilm: a well-designed protected environment. Med. Mycol.43(3), 191–208 (2005).
   PubMed Web of Science ®Google Scholar
• Kojic EM, Darouiche RO. Candida infections of medical devices. Clin. Microbiol. Rev.17(2), 255–267 (2004).
   PubMed Web of Science ®Google Scholar
• Nett J, Lincoln L, Marchillo K et al. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother.51(2), 510–520 (2007).
   PubMed Web of Science ®Google Scholar
• Nett J, Lincoln L, Marchillo K, Andes D. β-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis.195(11), 1705–1712 (2007).
   PubMed Web of Science ®Google Scholar
• Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob. Agents Chemother.51(4), 1520–1523 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother.46(6), 1773–1180 (2002).
   PubMed Web of Science ®Google Scholar
• Seidler M, Salvenmoser S, Muller FM. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int. J. Antimicrob. Agents28(6), 568–573 (2006).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. in vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother.46(12), 3846–3853 (2002).
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother.51(3), 968–974 (2007).
   PubMed Web of Science ®Google Scholar
• Ikeda F, Wakai Y, Matsumoto S et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother.44(3), 614–618 (2000).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob.Agents Chemother.46(6), 1857–1869 (2002).
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother.49(12), 4895–4902 (2005).
   PubMed Web of Science ®Google Scholar
• Hebert MF, Smith HE, Marbury TC et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.45(10), 1145–11452 (2005).
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prohylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother.49(4), 1331–1336 (2005).
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49(8), 3317–3324 (2005).
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J.25(12), 1110–1115 (2006).
   PubMed Web of Science ®Google Scholar
• Darouiche RO. Echinocandins: ask not what they can do for esophageal candidiasis – ask what studies of esophageal candidiasis can do for them. Clin. Infect. Dis.39(6), 850–852 (2004).
   PubMedGoogle Scholar
• Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol. Ther.20(4), 475–481 (2004).
   PubMed Web of Science ®Google Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis.39(6), 842–849 (2004).
   PubMed Web of Science ®Google Scholar
• de Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol. Ther.21(7), 899–907 (2005).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39 (10), 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis.34(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24(10), 654–661 (2005).
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet369(9572), 1519–1527 (2007).
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl J. Med.356(24), 2472–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347(25), 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• AmBisome® (amphotericin B liposome for injection) product information: Astellas Pharma, OK, USA, July (2005).
   Google Scholar
• Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis.45(7), 883–983 (2007).
   PubMed Web of Science ®Google Scholar
• Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs10(4), 239–253 (1992).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant38(1), 47–51 (2006).
   PubMed Web of Science ®Google Scholar
• Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol.45(8), 954–960 (2005).
   PubMed Web of Science ®Google Scholar
• Hebert MF, Blough DK, Townsend RW et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol.45(9), 1018–1024 (2005).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis.38(2), 161–189 (2004).
   PubMed Web of Science ®Google Scholar
• Cornely O, Lasso M, Betts R et al. Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of less common forms of invasive candidiasis (IC). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17–20 September 2006.
   Google Scholar